Please assess the completion status of the following clinical trial:

Trial Title: Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Phase 0:~Provide written informed consent and be between the ages of 18 and up, inclusive.~* Patient that is diagnosed as respectable locally pancreatic tumor~* Have a target tumor accessible for intratumoral administration by EUS (Endoscopic Ultrasound) guidance as determined by the physician performing the EUS guided LODER insertion.~* Have a Karnofsky performance status of ≥ 70%.~* Have a life expectancy of \>= 3 months.~* If female and of child-bearing potential, have a negative serum pregnancy test during screening.~* Agree to use of a barrier method of contraception if sexually active (both men and women) from the time of administration of the first treatment and for at least 8 weeks after treatment.~* Have serum creatinine \< 2.0 mg/dL, , PT, - INR \< 1.5 absolute neutrophil count (ANC) \> 1,000 x 103 cells/mL, platelets ≥ 75,000/mL, and hemoglobin \>= 10 mg/dL.~* Have screening procedures completed within 2 weeks of starting treatment.~* No other malignancy present that would interfere with the current intervention.~* Have measurable disease.~Phase I~* Provide written informed consent and be between the ages of 18 and up.~* Have an unresectable, locally advanced diagnosed or highly suspected adenocarcinoma of the pancreas. Or patients with a tumor and are not planed to undergo surgery due to a high surgical risk (e.g. coagulopathy or severe congestive heart failure).~* Allocated to receive standard of care chemo as first line treatment.~* Have a target tumor that is accessible for intratumoral administration by PTA or EUS guidance as determined by the radiologist/gastroenterologist performing the PTA/EUS injection.~* Have a Karnofsky performance status of ≥ 70%.~* Have a life expectancy of \>= 3 months.~* If female and of child-bearing potential, have a negative serum pregnancy test during screening.~* Agree to use of a barrier method of contraception if sexually active (both men and women) from the time of administration of the first treatment and for at least 8 weeks after treatment.~* Have serum creatinine \< 2.0 mg/dL, PT - INR \< 1.5, absolute neutrophil count (ANC) \> 1,000 x 103 cells/mL, platelets ≥ 75,000/mL, and hemoglobin \>= 10 mg/dL.~* Have screening procedures completed within 4 weeks of starting treatment.~* No other malignancy present that would interfere with the current intervention.~* Have measurable disease.~Exclusion Criteria:~Phase 0:~* Have distant metastasis spread (such as liver or lung, or lymph nodes metastases), peritoneal spread or malignant sites.~* Have clinically significant pancreatitis within 12 weeks of treatment.~* If female, be breast feeding.~* Have a medical condition contraindicated for both percutaneous- and endoscopic- guided delivery or any intercurrent medical illness or other medical condition that would in the judgment of the investigator compromise patient safety or the objectives of the study.~* Have a history of bleeding coagulopathy.~* Have participated in any therapeutic research study within the last 4 weeks.~Phase I:~* Have distant metastatic spread (such as liver, lung, or lymph nodes metastases), peritoneal spread or malignant sites.~* Have clinically significant pancreatitis within 12 weeks of treatment.~* If female, be breast feeding.~* Have a medical condition contraindicated for both percutaneous- and endoscopic- guided delivery or any intercurrent medical illness or other medical condition that would in the judgment of the investigator compromise patient safety or the objectives of the study.~* Have a history of bleeding coagulopathy.~* Have participated in any therapeutic research study within the last 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 arm (Type: EXPERIMENTAL): SOC + siG12D LODER

Based on this trial design, predict the completion outcome and termination type (if applicable).